In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity

References

• Adişen E, Aral A, Aybay C, Gürer MA. 2010. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study. J. Dermatol. 37:708–713.
   PubMed Web of Science ®Google Scholar
• Anderson P, Louie J, Lau A, Broder M. 2005. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep. 7:3–9.
   PubMedGoogle Scholar
• Anthony D, Lehmann P. 2003. T-Cell epitope mapping using the elispot approach. Methods. 29:260–269.
   PubMed Web of Science ®Google Scholar
• Arora T, Padaki R, Liu L, Hamburger A, Ellison A, Stevens S, Louie J, Kohno T. 2009. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 45:124–131.
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab M04-688 Study Group. 2010. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 37:299–310.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's Disease. N Engl J Med. 348:601–608.
   PubMed Web of Science ®Google Scholar
• Baker M, Jones T. 2007. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel. 10:219–227.
   PubMed Web of Science ®Google Scholar
• Baker M, Reynolds H, Lumicisi B, Bryson C. 2010. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself. 1:314–322.
   PubMedGoogle Scholar
• Bartelds G, Wijbrandts C, Nurmohamed M, Stapel S, Lems W, Aarden L, Dijkmans B, Tak P, Wolbink G. 2007. Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 66:921–926.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic M, Saxne T. 2006. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the TNFα inhibitor infliximab. Arthritis Rheum. 54:3782–3789.
   PubMed Web of Science ®Google Scholar
• Chirino A, Ary M, Marshall S. 2004. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today. 9:82–90.
   PubMed Web of Science ®Google Scholar
• de Vries M, Brouwer E, van der Horst-Bruinsma I, Spoorenberg A, van Denderen J, Jamnitski A, Nurmohamed M, Dijkmans B, Aarden L, Wolbink G. 2009. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis. 68:1787–1788.
   PubMed Web of Science ®Google Scholar
• de Vries M, van der Horst-Bruinsma I, Nurmohamed M, Aarden L, Stapel S, Peters M, van Denderen J, Dijkmans B, Wolbink G. 2009. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 68:531–535.
   PubMed Web of Science ®Google Scholar
• Delluc S, Ravot G, Maillere B. 2011. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J. 25:2040–2048.
   PubMed Web of Science ®Google Scholar
• Dery J-P, Braden GA, Lincoff AM, Kereiakes DJ, Browne K, Little T, George BS, Sane DC, Cines DB, Effron MB, et al. 2004. Final results of the ReoPro readministration registry. Am J Cardiol. 93:979–984.
   PubMed Web of Science ®Google Scholar
• Elliott M, Maini R, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan F, Walker J, Bijl H, Ghrayeb J. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36:1681–1690.
   PubMed Web of Science ®Google Scholar
• Gordon K, Gottlieb A, Leonardi C, Elewski B, Wang A, Jahreis A, Zitnik R. 2006. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 17:9–17.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Evans R, Li S, Dooley L, Guzzo C, Baker D, Bala M, Marano C, Menter A. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 51:534–542.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK, Kerdel FA, Calabro S, Wang J, Kerkmann U, et al. 2012. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multi-center, open-label study. J Am Acad Dermatol. 67:642–650.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J, Rachmilewitz D, Wolf D, Olson A, Bao W, et al. 2002. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Hartmann M, Enk A, Hadaschik E. 2011. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol. 165:1355–1358.
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. 2010. Transmembrane TNF-α: Structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 49:1215–1228.
   PubMed Web of Science ®Google Scholar
• Hwang W, Foote J. 2005. Immunogenicity of engineered antibodies. Methods. 36:3–10.
   PubMed Web of Science ®Google Scholar
• Jawa V, Cousens L, Awwad M, Wakshull E, Kropshofer H, de Groot A. 2013. T-Cell-dependent immunogenicity of protein therapeutics: Pre-clinical assessment and mitigation. Clin Immunol. 149:534–555.
   PubMed Web of Science ®Google Scholar
• Joubert M, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, Baker M, Herskovitz J, Goletz T, Zhou L, et al. 2016. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PLoS One. 11:e0159328.
   PubMed Web of Science ®Google Scholar
• Kamaté C, Lenting P, van den Berg H, Mutis T. 2007. Depletion of CD4+/CD35hi regulatory T-cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals. J Thromb Haemost. 5:611–613.
   PubMed Web of Science ®Google Scholar
• Knight D, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore M, Vilcek J, Daddona P. 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 30:1443–1453.
   PubMed Web of Science ®Google Scholar
• Krathen R, Berthelot C, Hsu S. 2006. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol. 5:251–254.
   PubMedGoogle Scholar
• Krieckaert C, Jamnitski A, Nurmohamed M, Kostense P, Boers M, Wolbink G. 2012. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treat-ment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum. 64:3850–3855.
   PubMed Web of Science ®Google Scholar
• Kubo C, Hayakawa M, Ito S, Kuramochi T, Iwata Y, Shioda A, Hara T, Inoue T, Mishima M. 2010. Helper T-cell proliferation assay to measure T-cell response to various antibody pharmaceuti-cals. 17^th Annual Meeting of Japanese Society of Immunotoxicology; Tsukuba, Japan.
   Google Scholar
• Lecluse L, Driessen R, Spuls P, de Jong E, Stapel S, van Doorn M, Bos J, Wolbink G. 2010. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 146:127–132.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Strober B, Gottlieb A, Elewski B, Ortonne J, van de Kerkhof P, Chiou C, Dunn M, Jahreis A. 2010. Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study. J Drugs Dermatol. 9:928–937.
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter D. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 98:3241–3248.
   PubMed Web of Science ®Google Scholar
• Mahil S, Arkir Z, Richards G, Lewis C, Barker J, Smith C. 2013. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: A single-centre, cohort study. Br J Dermatol. 169:306–313.
   PubMed Web of Science ®Google Scholar
• Maini R, Breedveld F, Kalden J, Smolen J, Davis D, Macfarlane J, Antoni C, Leeb B, Elliott M, Woody J, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-TNFα monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1552–1563.
   PubMed Web of Science ®Google Scholar
• Matucci A, Pratesi S, Petroni G, Nencini F, Virgili G, Milla M, Maggi E, Vultaggio A. 2013. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy. 43:659–664.
   PubMed Web of Science ®Google Scholar
• Mazilu D, Opriş D, Gainaru C, Iliuta M, Apetrei N, Luca G, Borangiu A, Gudu T, Peltea A, Groseanu L, et al. 2014. Monitoring drug and anti-drug levels: A rational approach in rheu-matoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed Res Intl. 2014:1.
   Google Scholar
• Menter A, Feldman S, Weinstein G, Papp K, Evans R, Guzzo C, Li S, Dooley L, Arnold C, Gottlieb A. 2007. A randomized comparison of continuous vs. Intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 56:e1–15.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring S, Gordon K, Kimball A, Leonardi C, Langley R, Strober B, Kaul M, Gu Y, Okun M, et al. 2008. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled Phase III trial. J Am Acad Dermatol. 58:106–115.
   PubMed Web of Science ®Google Scholar
• Papp K, Tyring S, Lahfa M, Prinz J, Griffiths C, Nakanishi A, Zitnik R, van de Kerkhof P, Melvin L. 2005. A global Phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol. 152:1304–1312.
   PubMed Web of Science ®Google Scholar
• Paramarta J, Baeten D. 2014. Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: No association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res Ther. 16:R160.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency. Summary of Common Technical Document for Etanercept. Approved January 19, 2005.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. Summary of Common Technical Document for Infliximab. Approved January 17, 2002.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. Summary of Common Technical Document for Adalimumab. Approved April 16, 2008.
   Google Scholar
• Reich K, Nestle F, Papp K, Ortonne J, Evans R, Guzzo C, Li S, Dooley L, Griffiths C. 2005. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet. 366:1367–1374.
   PubMed Web of Science ®Google Scholar
• Ritter G, Cohen L, Williams C, Richards E, Old L, Welt S. 2001. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 61:6851–6859.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Hanauer S, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D, Panaccione R, Wolf D, Kent J, Bittle B, et al. 2007. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut. 56:1232–1239.
   PubMed Web of Science ®Google Scholar
• Sands B, Anderson F, Bernstein C, Chey W, Feagan B, Fedorak R, Kamm M, Korzenik J, Lashner B, Onken J, et al. 2004. Infliximab maintenance therapy for fistulizing Crohn's Disease. N Engl J Med. 350:876–885.
   PubMed Web of Science ®Google Scholar
• Schellekens H. 2003. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 18:1257–1259.
   PubMed Web of Science ®Google Scholar
• Schultz H, Reedtz-Runge S, Backstrom B, Lamberth K, Pedersen C, Kvarnhammar A, Consortium A. 2017. Quantitative analysis of the CD4+ T-cell response to therapeutic antibodies in healthy donors using a novel T-cell: PBMC assay. PLoS One. 12:e0178544.
   PubMed Web of Science ®Google Scholar
• Stickler M, Rochanayon N, Razo O, Mucha J, Gebel W, Faravashi N, Chin R, Holmes S, Harding F. 2004. An in vitro human cell-based assay to rank the relative immunogenicity of proteins. Toxicol. Sci. 77:280–289.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. 2013. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 40:39–42.
   PubMed Web of Science ®Google Scholar
• Tcheng J, Kereiakes D, Lincoff A, George B, Kleiman N, Sane D, Cines D, Jordan R, Mascelli M, Langrall M, et al. 2001. Abciximab readministration: Results of ReoPro re-administration registry. Circulation. 104:870–875.
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H. Japanese Infliximab Study investigators. 2010. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A random-ized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 59:40–49.
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H. Japanese Infliximab Study investigators. 2011. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 38:321–334.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon K, Poulin Y, Langley R, Gottlieb A, Dunn M, Jahreis A. 2007. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 143:719–726.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. 2001. SIMULECT Supplement BLA, Proposed Labeling. Released March 19, 2001.
   Google Scholar
• US Food and Drug Administration. 2013. Reopro, Abciximab, Label information. November 26, 2013.
   Google Scholar
• van Kuijk A, de Groot M, Stapel S, Dijkmans B, Wolbink G, Tak P. 2010. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 69:624–625.
   PubMed Web of Science ®Google Scholar
• van Walle I, Gansemans Y, Parren P, Stas P, Lasters I. 2007. Immunogenicity screening in protein drug development. Expert Opin Biol Ther. 7:405–418.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, van Assche G, Baert F, D'Haens G, Rutgeerts P. 2007. Effectiveness of concomitant immunosuppressive therapy in suppressing formation of antibodies to infliximab in Crohn's disease. Gut. 56:1226–1231.
   PubMed Web of Science ®Google Scholar
• Welt S, Ritter G, Williams C, Cohen LS, Jungbluth A, Richards EA, Old LJ, Kemeny NE. 2003. Preliminary report of a Phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 9:1347–1353.
   PubMed Web of Science ®Google Scholar
• West R, Zelinkova Z, Wolbink G, Kuipers E, Stokkers P, van der Woude C. 2008. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 28:1122–1126.
   PubMed Web of Science ®Google Scholar
• Wolbink G, Vis M, Lems W, Voskuyl A, de Groot E, Nurmohamed M, Stapel S, Tak P, Aarden L, Dijkmans B. 2006. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54:711–715.
   PubMed Web of Science ®Google Scholar
• Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, et al. 2015. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis. J Rheumatol. 42:73–78.
   PubMed Web of Science ®Google Scholar